by Daniel X. Thomas
In the present blog, we will concentrate on the impact of G 1/24 on the Guidelines.
The EPO has called for comments, but the position taken in the new Chapters F-IV, 4,1 and 4.2 will most probably not be amended by the comments.
The new parts of the Guidelines
4.1 Clarity
Art.
by Daniel X. Thomas
EP 3 263 001 B1 relates to a removable point-of-care hygiene compliance module for a dispensing container
Brief outline of the case
The OD decided that claim 1 as granted infringed Art 123(2). The same applied to AR1-4.
The OD maintained the patent according to AR5.
by Daniel X. Thomas
EP 2 817 000 B1 relates to oral pharmaceutical compositions comprising dabigatran etexilate mesylate.
Brief outline of the case
The OD decided maintenance according a new MR= MRn.
Opponent 1 withdrew its opposition and opponents 2+3 appealed.
The board held that claim 1 as maintained lacked IS over D1=WO 2012/001156.
by Daniel X. Thomas
EP 3 686 882 A1 filed as PCT/CN2018/092114 relates to a filtering model training method, a speech recognition method, a training device, a speech recognition device, and a speech recognition system.
Brief outline of the case
The application was refused for lack of clarity of the claims of the MR aa well as AR1-3.
by Daniel X. Thomas
EP 3 525 706 B1 relates to the field of Cold Atmospheric Plasma (CAP) treatment of therapy-refractory Actinic Keratosis, wherein the cold atmospheric plasma is an argon-containing plasma.
Brief outline of the procedure
The OD rejected the opposition and Opponent 2 appealed.
The board decided that claim 1 as granted lack IS over D1=US 2013/0345620 in view an expectation of success.